

Michele M Castro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4035374/publications.pdf>

Version: 2024-02-01

51
papers

1,855
citations

236612

25
h-index

253896

43
g-index

52
all docs

52
docs citations

52
times ranked

2016
citing authors

#	ARTICLE	IF	CITATIONS
1	Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats. <i>Atherosclerosis</i> , 2008, 198, 320-331.	0.4	170
2	Antioxidant treatment reduces matrix metalloproteinase-2-induced vascular changes in renovascular hypertension. <i>Free Radical Biology and Medicine</i> , 2009, 46, 1298-1307.	1.3	143
3	Matrix Metalloproteinase 2 as a Potential Mediator of Vascular Smooth Muscle Cell Migration and Chronic Vascular Remodeling in Hypertension. <i>Journal of Vascular Research</i> , 2015, 52, 221-231.	0.6	101
4	Imbalance between matrix metalloproteinases and tissue inhibitor of metalloproteinases in hypertensive vascular remodeling. <i>Matrix Biology</i> , 2010, 29, 194-201.	1.5	100
5	Spironolactone and hydrochlorothiazide exert antioxidant effects and reduce vascular matrix metalloproteinase activity and expression in a model of renovascular hypertension. <i>British Journal of Pharmacology</i> , 2010, 160, 77-87.	2.7	86
6	Matrix metalloproteinases: Targets for doxycycline to prevent the vascular alterations of hypertension. <i>Pharmacological Research</i> , 2011, 64, 567-572.	3.1	80
7	Matrix metalloproteinase inhibitor properties of tetracyclines: Therapeutic potential in cardiovascular diseases. <i>Pharmacological Research</i> , 2011, 64, 551-560.	3.1	80
8	Matrix Metalloproteinase Inhibition Improves Cardiac Dysfunction and Remodeling in 2-Kidney, 1-Clip Hypertension. <i>Journal of Cardiac Failure</i> , 2010, 16, 599-608.	0.7	67
9	Low level and sub-chronic exposure to methylmercury induces hypertension in rats: nitric oxide depletion and oxidative damage as possible mechanisms. <i>Archives of Toxicology</i> , 2009, 83, 653-662.	1.9	64
10	Atorvastatin enhances sildenafil-induced vasodilation through nitric oxide-mediated mechanisms. <i>European Journal of Pharmacology</i> , 2004, 498, 189-194.	1.7	62
11	Doxycycline ameliorates 2K-1C hypertension-induced vascular dysfunction in rats by attenuating oxidative stress and improving nitric oxide bioavailability. <i>Nitric Oxide - Biology and Chemistry</i> , 2012, 26, 162-168.	1.2	60
12	Inhibition of matrix metalloproteinase activity in vivo protects against vascular hyporeactivity in endotoxemia. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2010, 298, H45-H51.	1.5	58
13	Quercetin decreases the activity of matrix metalloproteinase-2 and ameliorates vascular remodeling in renovascular hypertension. <i>Atherosclerosis</i> , 2018, 270, 146-153.	0.4	49
14	Inhibition of Matrix Metalloproteinases (MMPs) as a Potential Strategy to Ameliorate Hypertension-Induced Cardiovascular Alterations. <i>Current Drug Targets</i> , 2013, 14, 335-343.	1.0	49
15	Doxycycline Dose-dependently Inhibits MMP-mediated Vascular Changes in 2K1C Hypertension. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2011, 108, 318-325.	1.2	48
16	Lercanidipine reduces matrix metalloproteinase-2 activity and reverses vascular dysfunction in renovascular hypertensive rats. <i>European Journal of Pharmacology</i> , 2008, 591, 224-230.	1.7	47
17	Metalloproteinase inhibition protects against cardiomyocyte injury during experimental acute pulmonary thromboembolism*. <i>Critical Care Medicine</i> , 2011, 39, 349-356.	0.4	47
18	Tempol inhibits TGF- β 2 and MMPs upregulation and prevents cardiac hypertensive changes. <i>International Journal of Cardiology</i> , 2013, 165, 165-173.	0.8	45

#	ARTICLE	IF	CITATIONS
19	Quercetin restores plasma nitrite and nitroso species levels in renovascular hypertension. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2010, 382, 293-301.	1.4	44
20	Matrix Metalloproteinase-2 Proteolysis of Calponin-1 Contributes to Vascular Hypocontractility in Endotoxemic Rats. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012, 32, 662-668.	1.1	40
21	Nitrite or sildenafil, but not BAY 41-2272, blunt acute pulmonary embolism-induced increases in circulating matrix metalloproteinase-9 and oxidative stress. <i>Thrombosis Research</i> , 2009, 124, 349-355.	0.8	32
22	Contrasting effects of aliskiren versus losartan on hypertensive vascular remodeling. <i>International Journal of Cardiology</i> , 2013, 167, 1199-1205.	0.8	32
23	The potential of stimulating nitric oxide formation in the treatment of hypertension. <i>Expert Opinion on Therapeutic Targets</i> , 2017, 21, 543-556.	1.5	32
24	Lercanidipine decreases vascular matrix metalloproteinase-2 activity and protects against vascular dysfunction in diabetic rats. <i>European Journal of Pharmacology</i> , 2008, 599, 110-116.	1.7	30
25	Matrix metalloproteinase (MMP)-2 activation by oxidative stress decreases aortic calponin-1 levels during hypertrophic remodeling in early hypertension. <i>Vascular Pharmacology</i> , 2019, 116, 36-44.	1.0	29
26	Doxycycline Reduces Cardiac Matrix Metalloproteinase-2 Activity but Does not Ameliorate Myocardial Dysfunction During Reperfusion in Coronary Artery Bypass Patients Undergoing Cardiopulmonary Bypass. <i>Critical Care Medicine</i> , 2013, 41, 2512-2520.	0.4	25
27	Remodeling of Aorta Extracellular Matrix as a Result of Transient High Oxygen Exposure in Newborn Rats: Implication for Arterial Rigidity and Hypertension Risk. <i>PLoS ONE</i> , 2014, 9, e92287.	1.1	25
28	Matrix metalloproteinase (MMP)-2 decreases calponin-1 levels and contributes to arterial remodeling in early hypertension. <i>Biochemical Pharmacology</i> , 2016, 118, 50-58.	2.0	24
29	Nitrite exerts antioxidant effects, inhibits the mTOR pathway and reverses hypertension-induced cardiac hypertrophy. <i>Free Radical Biology and Medicine</i> , 2018, 120, 25-32.	1.3	24
30	Long-Term Excessive Selenium Supplementation Induces Hypertension in Rats. <i>Biological Trace Element Research</i> , 2018, 182, 70-77.	1.9	24
31	Nitrite treatment downregulates vascular MMP-2 activity and inhibits vascular remodeling in hypertension independently of its antihypertensive effects. <i>Free Radical Biology and Medicine</i> , 2019, 130, 234-243.	1.3	24
32	Evidence of early involvement of matrix metalloproteinase-2 in lead-induced hypertension. <i>Archives of Toxicology</i> , 2009, 83, 439-449.	1.9	22
33	Reduced levels of potential circulating biomarkers of cardiovascular diseases in apparently healthy vegetarian men. <i>Clinica Chimica Acta</i> , 2016, 461, 110-113.	0.5	15
34	Inhibitory effects of caspase inhibitors on the activity of matrix metalloproteinase-2. <i>Biochemical Pharmacology</i> , 2013, 86, 469-475.	2.0	12
35	Matrix Metalloproteinase-2 Activity is Associated with Divergent Regulation of Calponin-1 in Conductance and Resistance Arteries in Hypertension-Induced Early Vascular Dysfunction and Remodelling. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2017, 121, 246-256.	1.2	11
36	MMP inhibition attenuates hypertensive eccentric cardiac hypertrophy and dysfunction by preserving troponin I and dystrophin. <i>Biochemical Pharmacology</i> , 2021, 193, 114744.	2.0	11

#	ARTICLE	IF	CITATIONS
37	Verapamil decreases calpain-1 and matrix metalloproteinase-2 activities and improves hypertension-induced hypertrophic cardiac remodeling in rats. <i>Life Sciences</i> , 2020, 244, 117153.	2.0	10
38	Ethanol withdrawal increases blood pressure and vascular oxidative stress: a role for angiotensin type 1 receptors. <i>Journal of the American Society of Hypertension</i> , 2018, 12, 561-573.	2.3	9
39	Study of the Biomechanical and Histological Properties of the Abdominal Aorta of Diabetic Rats Exposed to Cigarette Smoke. <i>Journal of Vascular Research</i> , 2019, 56, 255-266.	0.6	6
40	Omeprazole induces vascular remodeling by mechanisms involving xanthine oxidoreductase and matrix metalloproteinase activation. <i>Biochemical Pharmacology</i> , 2021, 190, 114633.	2.0	5
41	Targeting Matrix Metalloproteinases in Disease Conditions. <i>Acupuncture in Medicine</i> , 2014, 32, 373-375.	0.4	4
42	Inhibition of Matrix Metalloproteinases (MMPs) as a Potential Strategy to Ameliorate Hypertension-Induced Cardiovascular Alterations. <i>Current Drug Targets</i> , 2013, 14, 335-343.	1.0	3
43	Metabolic parameters and responsiveness of isolated iliac artery in LDLr mice: role of aerobic exercise training. <i>American Journal of Cardiovascular Disease</i> , 2017, 7, 64-71.	0.5	2
44	Smoothelin-B is not a target of matrix metalloproteinase (MMP)-2 in the vasculature of endotoxemic rats. <i>Canadian Journal of Physiology and Pharmacology</i> , 2014, 92, 887-891.	0.7	1
45	Lack of scarring is not always a sign of cardiac health: Functional and molecular characterization of the rat heartâ€™s following chronic reperfusion. <i>PLoS ONE</i> , 2018, 13, e0209190.	1.1	1
46	Matrix Metalloproteinases and Hypertension. , 2014, , 279-293.		1
47	Low load strength training, associated with or without blood flow restriction increased NO production and decreased production of reactive oxygen species in rats aorta. <i>Life Sciences</i> , 2022, 294, 120350.	2.0	1
48	[PP.22.25] SODIUM OVERLOAD AFFECTS THE SYMPATHOVAGAL BALANCE AND INDUCES MORPHOLOGICAL AND FUNCTIONAL CHANGES IN RAT AORTA. <i>Journal of Hypertension</i> , 2017, 35, e283.	0.3	0
49	Reply to: â€œQuercetin affects gelatinases in rat aortas: Some commentsâ€• <i>Atherosclerosis</i> , 2018, 275, 446-447.	0.4	0
50	Smoothelinâ€™: a potential target of matrix metalloproteinase (MMP)â€™ in the vasculature of endotoxemic rats. <i>FASEB Journal</i> , 2011, 25, 1115.19.	0.2	0
51	Inhibitory effects of caspase inhibitors on the activity of matrix metalloproteinase (MMP)â€™. <i>FASEB Journal</i> , 2012, 26, 1b657.	0.2	0